Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin.

Zhong Y, Tang H, Zeng Q, Wang X, Yi G, Meng K, Mao Y, Mao X.

Ups J Med Sci. 2012 Nov;117(4):390-8. doi: 10.3109/03009734.2012.672345. Epub 2012 Sep 25.

2.

The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.

Semenova AE, Sergienko IV, Masenko VP, Ezhov MV, Gabrusenko SA, Kuharchuk VV, Belenkov YN.

Acta Cardiol. 2009 Jun;64(3):405-9.

PMID:
19593954
3.

Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).

Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators.

Circ J. 2009 Nov;73(11):2110-7. Epub 2009 Oct 5.

5.

NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.

Satoh M, Tabuchi T, Itoh T, Nakamura M.

Clin Sci (Lond). 2014 Feb;126(3):233-41. doi: 10.1042/CS20130043.

PMID:
23944632
6.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

7.

Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.

Hong YJ, Jeong MH, Choi YH, Ma EH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Youn HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC.

Am J Cardiol. 2010 Nov 1;106(9):1241-7. doi: 10.1016/j.amjcard.2010.06.046. Epub 2010 Sep 9.

PMID:
21029819
8.

Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).

Kawashiri MA, Yamagishi M, Sakamoto T, Takayama T, Hiro T, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators.

Cardiovasc Ther. 2013 Dec;31(6):335-43. doi: 10.1111/1755-5922.12027.

9.

Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin.

Tziakas D, Chalikias G, Kapelouzou A, Tentes I, Schäfer K, Karayannakos P, Kostakis A, Boudoulas H, Konstantinides S.

Int J Cardiol. 2013 Dec 10;170(2):173-81. doi: 10.1016/j.ijcard.2013.10.070. Epub 2013 Oct 26.

PMID:
24215985
10.
11.

Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.

Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC.

Circ J. 2011;75(2):398-406. Epub 2010 Dec 9.

12.

Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.

Chitose T, Sugiyama S, Sakamoto K, Shimomura H, Yamashita T, Hokamaki J, Tsunoda R, Shiraishi S, Yamashita Y, Ogawa H.

Atherosclerosis. 2014 Nov;237(1):251-8. doi: 10.1016/j.atherosclerosis.2014.08.053. Epub 2014 Sep 16.

PMID:
25262434
13.

Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).

Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Park SW, Park SJ.

Am J Cardiol. 2012 Jun 15;109(12):1700-4. doi: 10.1016/j.amjcard.2012.01.399. Epub 2012 Mar 20.

PMID:
22440123
14.

Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.

Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M; Kishiwada Atherosclerosis Prevention Study (KAPS) Group.

Cardiovasc Ther. 2014 Jun;32(3):97-104. doi: 10.1111/1755-5922.12066.

PMID:
24456217
15.

Factors underlying regression of coronary atheroma with potent statin therapy.

Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, St John J, Wolski K, Uno K, Kataoka Y, Nicholls SJ.

Eur Heart J. 2013 Jun;34(24):1818-25. doi: 10.1093/eurheartj/eht084. Epub 2013 May 3.

PMID:
23644179
16.
17.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators.

JAMA. 2006 Apr 5;295(13):1556-65. Epub 2006 Mar 13.

PMID:
16533939
18.
20.

Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study.

Lemos MM, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, Draibe SA, Canziani ME.

Clin Nephrol. 2013 Jul;80(1):1-8. doi: 10.5414/CN107630.

PMID:
23442255

Supplemental Content

Support Center